ABCL News and Press, AbCellera Biologics Inc. From 08/14/22

AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to fur...

Shares of AbCellera Biologics ( NASDAQ: ABCL ) gained 16.7% to $12.98 in Wednesday afternoon trading, as investors looked past the company's Q2 results miss to focus on continued strength from COVID-19 royalties and a sustained increase in discovery programs. ABCL after ...

Shares of biopharmaceutical developer AbCellera Biologics (NASDAQ: ABCL) are up 19.1% as of 11:51 a.m. ET Wednesday, according to data from S&P Global Market Intelligence , down from its midday peak near 23.7%. The surge follows yesterday's post-close release of mixed second...

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Call Transcript ...

AbCellera Biologics Inc. (ABCL) Q2 2022 Earnings Conference Call August 09, 2022, 05:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Ti...

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2022 Q2 earnings call. For further details see: AbCellera Biologics Inc. 2022 Q2 - Results - Earnings Call Presentation

AbCellera Biologics press release ( NASDAQ: ABCL ): Q2 GAAP EPS of -$0.02 misses by $0.03 . Revenue of $45.6M (+65.2% Y/Y) misses by $15.62M . $1,022M of cash, cash equivalents, and marketable securities. For further details see: AbCellera Biologics G...

Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of ($0.02) per share on a basic and diluted basis compared to ($0.01) (basic and diluted) per share in Q2...

Eli Lilly ( NYSE: LLY ) announced that the FDA had updated the authorization granted for its COVID-19 antibody therapy bebtelovimab allowing its commercial availability from next week through the drug distributor AmerisourceBergen ( ABC ). Per the previous authorizatio...

AbCellera Biologics ( NASDAQ: ABCL ) has entered into a partnership with Atlas Ventures to discover therapeutic antibodies for up to three drug targets . Terms call for Atlas to have the right to develop and commercialize therapeutic antibodies resulting from the colla...